title: Oxidative stress and antioxidant strategies in newborns.
abstract: Oxidative stress (OS) is defined as an unbalance between prooxidant and antioxidant factors that can lead to cellular and tissue damage.The newborn, especially if preterm, is highly prone to OS and to the toxic effect of free radicals (FR). At birth, the newborn is exposed to a relatively hyperoxic environment caused by an increased oxygen bioavailability with greatly enhanced generation of FR. Additional sources (inflammation, hypoxia, ischemia, glutamate, and free iron release) occur magnifying OS. In the preterm baby, the perinatal transition is accompanied by the immaturity of the antioxidant systems and the reduced ability to induce efficient homeostatic mechanisms designed to control overproduction of cell-damaging FR. Improved understanding of the pathophysiological mechanism involved in perinatal brain lesions helps to identify potential targets for neuroprotective interventions, and the knowledge of these mechanisms has enabled scientists to develop new therapeutic strategies that have confirmed their neuroprotective effects in animal studies. Considering the growing role of OS in preterm newborn morbidity in respect to the higher risk of FR damage in these babies, a strict control of oxygen administration, lutein, melatonin, and hypothermia show great promise as potential neuroprotectants. This review provides an overview of the pathogenesis of free radical-mediated diseases of the newborn and the antioxidant strategies for now tested to reduce the OS and its damaging effects.
authors.affiliation: Department of Pediatrics, Obstetrics and Reproductive Medicine, University of Siena, Italy.
authors.forename: Serafina
authors.initials: S
authors.lastname: Perrone
authors.forename: Simona
authors.initials: S
authors.lastname: Negro
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Tataranno
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Buonocore
mesh_terms: D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D005609:Free Radicals / Q000009:adverse effects / Q000378:metabolism; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000209:etiology* / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*
chemical_list: D000975:Antioxidants; D005609:Free Radicals; D018696:Neuroprotective Agents